Awarding of Orphan Drug Designation by the FDA

Summary by AI BETAClose X

CRISM Therapeutics Corporation has received Orphan Drug Designation from the U.S. Food and Drug Administration for irinotecan in the treatment of malignant glioma, a designation that offers seven years of U.S. market exclusivity upon approval, tax credits for clinical trials, and fee exemptions. This regulatory milestone, following the UK's Innovation Passport for the ChemoSeed platform, significantly enhances the strategic and commercial profile of the irinotecan-ChemoSeed program, positioning it for coordinated regulatory interaction across major jurisdictions as the Phase 2 clinical trial progresses.

Disclaimer*

UK 100

Latest directors dealings